Literature Highlights

Back to Publications To Literature Searches

Each month the Lupus Forum Steering Committee selects the latest published original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

View Slides

Literature Highlights - September 2025

more…

Keywords:

Clinical care, EULAR, Efficacy, JAK, Personalized medicine, Phase 2, Recommendations, Safety, SLE, Upadacitinib

View Slides

Literature Highlights - August 2025

more…

Keywords:

CAR T cell therapy · Systemic lupus erythematosus · Systematic review, Efficacy, Phase 2, PK/PD, Renal, Safety, Outcomes.

View Slides

Literature Highlights - July 2025

more…

Keywords:

Voclosporin, outcomes, renal, safety, lupus nephritis

View Slides

Literature Highlights - June 2025

more…

Keywords:

SLE, deucravacitinib, patient-reported outcomes, PAISLEY, belimumab, early treatment, ACR, Guidelines.

View Slides

Literature Highlights - May 2025

more…

Keywords:

Delphi; SLE; Treatment Response Measure for Systemic Lupus Erythematosus, LTE, Outcomes.

View Slides

Literature Highlights - April 2025

more…

Keywords:

Autoimmunity, Belimumab, B cells, immune cells, IPTW, LLDAS, machine learning, single cell RNA sequencing, Systemic lupus erythematosus, Telitacicept.

View Slides

Literature Highlights - March 2025

more…

Keywords:

B-cell, BAFF, IL-6, biomarker, SLE, biologics, belimumab, mucocutaneous, disease activity, Anifrolumab, LLDAS, DORIS, Remission, LTE

View Slides

Literature Highlights - February 2025

more…

Keywords:

BAFF, Belimumab, B cell depletion, CAR T cells, CD20, Lupus Erythematosus, Lupus Nephritis, Monoclonal antibody, Obinutuzumab, Renal response, Rituximab, SLE, Telitacicept

View Slides

Literature Highlights - January 2025

more…

Keywords:

HDAS, CLE, LLDAS, APLAR, Deucravacitinib

View Slides

Literature Highlights - December 2024

more…

Keywords:

Efficacy, IL-6, Tolerability, Phase 2, Safety, Cenerimod, LN, proteinuria, voclosporin, GC,